These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 22681512)

  • 61. Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report.
    Vicente-Valor MI; Garcia-Llopis P; Mejia Andujar L; Antonino de la Camara G; García del Busto N; Lopez Tinoco MJ; Quintana Vergara B; Peiro Vilaplana C; Dominguez Moran JA; Sánchez Alcaraz A
    J Clin Pharm Ther; 2013 Feb; 38(1):71-3. PubMed ID: 22726074
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways.
    Centonze D
    Eur Neurol; 2014; 72 Suppl 1():6-8. PubMed ID: 25278116
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.
    Feliú A; Moreno-Martet M; Mecha M; Carrillo-Salinas FJ; de Lago E; Fernández-Ruiz J; Guaza C
    Br J Pharmacol; 2015 Jul; 172(14):3579-95. PubMed ID: 25857324
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study.
    Patti F; Chisari CG; Solaro C; Benedetti MD; Berra E; Bianco A; Bruno Bossio R; Buttari F; Castelli L; Cavalla P; Cerqua R; Costantino G; Gasperini C; Guareschi A; Ippolito D; Lanzillo R; Maniscalco GT; Matta M; Paolicelli D; Petrucci L; Pontecorvo S; Righini I; Russo M; Saccà F; Salamone G; Signoriello E; Spinicci G; Spitaleri D; Tavazzi E; Trotta M; Zaffaroni M; Zappia M;
    Neurol Sci; 2020 Oct; 41(10):2905-2913. PubMed ID: 32335779
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Advances in the management of MS symptoms: real-life evidence.
    Trojano M
    Neurodegener Dis Manag; 2015; 5(6 Suppl):19-21. PubMed ID: 26611267
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis.
    Carod-Artal FJ; Adjamian P; Vila Silván C; Bagul M; Gasperini C
    Expert Rev Neurother; 2022 Jun; 22(6):499-511. PubMed ID: 35582858
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Assessment of the effectiveness and safety of Sativex® in compassionate use].
    Cimas-Hernando I; Pato-Pato A; Lorenzo-González JR; Rodríguez-Constenla I
    Rev Neurol; 2015 Mar; 60(5):202-6. PubMed ID: 25710689
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.
    Patti F
    Eur Neurol; 2016; 75 Suppl 1():9-12. PubMed ID: 26901344
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Advances in the management of multiple sclerosis symptoms: pathophysiology and assessment of spasticity in multiple sclerosis.
    Tintoré M
    Neurodegener Dis Manag; 2015; 5(6 Suppl):15-7. PubMed ID: 26611266
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis: Rationale, study design, and methodology.
    Russo M; Dattola V; Logiudice AL; Ciurleo R; Sessa E; De Luca R; Bramanti P; Bramanti A; Naro A; Calabrò RS
    Medicine (Baltimore); 2017 Nov; 96(46):e8826. PubMed ID: 29145345
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation.
    Russo M; Calabrò RS; Naro A; Sessa E; Rifici C; D'Aleo G; Leo A; De Luca R; Quartarone A; Bramanti P
    Neural Plast; 2015; 2015():656582. PubMed ID: 25699191
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity.
    Conte A; Vila Silván C
    Neurodegener Dis; 2021; 21(3-4):55-62. PubMed ID: 34731865
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
    Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
    Mult Scler; 2008 Jun; 14(5):679-90. PubMed ID: 18566030
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Multiple sclerosis spasticity: 'state-of-the-art' questionnaire survey of specialized healthcare professionals.
    Collongues N; Vermersch P
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):21-5. PubMed ID: 23369056
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Costs and quality of life of multiple sclerosis in Germany.
    Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S34-44. PubMed ID: 17310337
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.
    Lus G; Cantello R; Danni MC; Rini A; Sarchielli P; Tassinari T; Signoriello E
    Neurodegener Dis Manag; 2018 Apr; 8(2):105-113. PubMed ID: 29683408
    [TBL] [Abstract][Full Text] [Related]  

  • 77. What's new in multiple sclerosis spasticity research? Poster session highlights.
    Linker R
    Neurodegener Dis Manag; 2017 Nov; 7(6s):51-53. PubMed ID: 29143588
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Development of a population-based cost-effectiveness model of chronic graft-versus-host disease in Spain.
    Crespo C; Pérez-Simón JA; Rodríguez JM; Sierra J; Brosa M
    Clin Ther; 2012 Aug; 34(8):1774-87. PubMed ID: 22835778
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis.
    Centonze D; Mori F; Koch G; Buttari F; Codecà C; Rossi S; Cencioni MT; Bari M; Fiore S; Bernardi G; Battistini L; Maccarrone M
    Neurol Sci; 2009 Dec; 30(6):531-4. PubMed ID: 19768368
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The high cost of spasticity in multiple sclerosis to individuals and society.
    Stevenson VL; Gras A; Bárdos JI; Broughton J
    Mult Scler; 2015 Oct; 21(12):1583-92. PubMed ID: 25623252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.